ALTO-207

ALTO-207 is a fixed-dose, modified-release combination of pramipexole (a dopamine D3-preferring D2/D3 agonist approved for Parkinson's disease and restless legs syndrome) and ondansetron (a 5-HT3 antagonist antiemetic), being developed by Alto Neuroscience for treatment-resistant depression[2]. The compound is now in a Phase 2b placebo-controlled trial (NCT07553637) enrolling approximately 178 adults with TRD across U.S. and U.K. sites, with target dosing of 3.2 mg pramipexole and 15 mg ondansetron per day over an eight-week treatment period[1][2]. Topline data are guided for the second half of 2027[2]. The investment case rests on two prior data points. First, a Phase 2a trial in 32 MDD patients (originally run by Chase Therapeutics as CTC-501, the asset Alto acquired) showed a statistically significant MADRS improvement versus placebo with Cohen's d of 1.67 at Week 6 and 1.1 at Week 8[7]. In psychiatry trials, effect sizes for approved antidepressants typically fall in the 0.3 to 0.5 range, so an effect size above 1.0 is exceptionally large, though n=32 leaves substantial uncertainty about replication. Second, the independent PAX-D study, published in The Lancet Psychiatry in July 2025, found that adjunctive pramipexole at 2.5 mg produced a Cohen's d of 0.87 versus placebo in TRD, validating the dopamine-agonist hypothesis but with notable adverse-event burden[8]. ALTO-207's specific premise is that the ondansetron component blocks the dose-limiting nausea, enabling higher pramipexole exposure and better efficacy without the tolerability cliff. This is a repurposed-combination bet on a validated mechanism, not a novel-target shot in the dark.

ALTO-207 is investigational and not approved anywhere, but both component drugs are FDA-approved generics with long safety records. Phase 2b is enrolling per ClinicalTrials.gov[1], and Alto has publicly guided topline data to the second half of 2027[2]. No FDA expedited designations (breakthrough therapy, fast track, RMAT) have been announced specifically for ALTO-207. Alto Neuroscience IPO'd in early 2024 and has since had a turbulent pipeline year: ALTO-100 missed its primary endpoint in a Phase 2b major depressive disorder readout in October 2024[3], and ALTO-101 also recently missed[4]. In response, the company closed a $120 million PIPE financing in March 2026, lifting cash, cash equivalents, and restricted cash to roughly $264 million and extending guided runway through 2029, which the company states covers a potential NDA filing for ALTO-207[4]. Q1 2026 R&D spend rose to $20.3 million from $10.0 million in Q1 2025 as multiple Phase 2b programs ramped[4]. The 178-patient enrollment target and an eight-week active treatment period are consistent with a confirmatory rather than exploratory study. Placebo is the only comparator, which is the standard arm for new TRD entrants outside of esketamine (Spravato).

ALTO-207 has a fully discussable pharmacological story. Pramipexole is a dopamine D3-preferring D2/D3 receptor agonist. Mesolimbic dopamine signaling is the leading neurobiological substrate for reward processing, motivation, and anhedonia. Anhedonia (the inability to experience pleasure) is a core feature of treatment-resistant depression and is poorly addressed by serotonin-focused antidepressants like SSRIs and SNRIs. The dopamine-deficit hypothesis predicts that dopaminergic enhancement should specifically benefit the anhedonic and reward-impaired subset of depressed patients. Multiple small clinical trials going back to the early 2000s have tested pramipexole in depression with promising but inconsistent signals, and the recently published PAX-D study (a 150-patient randomized placebo-controlled trial led by University of Oxford and funded by the U.K. National Institute for Health and Care Research) confirmed a Cohen's d of 0.87 at the 2.5 mg target dose[8]. The persistent obstacle in all prior pramipexole depression work has been nausea: pramipexole stimulates the area postrema (the brain's chemoreceptor trigger zone), causing dose-limiting nausea and vomiting before the optimal antidepressant dose can be reached. Ondansetron, a 5-HT3 receptor antagonist used widely as an antiemetic in chemotherapy, blocks signaling at the same site. The fixed-dose modified-release combination is engineered specifically to use ondansetron to suppress pramipexole-induced nausea, enabling rapid titration to a higher pramipexole exposure (3.2 mg target versus 2.5 mg in PAX-D) that the company believes is the efficacy sweet spot. Alto's broader EEG-biomarker platform may eventually be used to enrich for dopamine-deficient phenotypes most likely to respond, though it is not clear from public materials that the Phase 2b enrolls on an EEG-selected basis.

NCT07553637 is a Phase 2b randomized, double-blind, placebo-controlled study in adults with treatment-resistant depression, enrolling approximately 178 patients across U.S. and U.K. sites, randomized 1:1 to ALTO-207 or placebo for an eight-week active treatment period[1][2]. Target dosing is 3.2 mg pramipexole plus 15 mg ondansetron per day, titrated up over the early weeks[2]. The primary endpoint is change from baseline in MADRS (Montgomery-Asberg Depression Rating Scale) total score, which is the FDA-aligned standard for depression trials[1][2]. MADRS is a clinician-rated scale where a 10-point drop is generally considered clinically meaningful, and placebo arms in TRD trials routinely produce response rates of 35 to 45 percent on this measure, which is the central efficacy headwind in psychiatry. TRD inclusion criteria per the registry require failure of two to five prior antidepressant trials of adequate dose and duration in the current depressive episode[1]. Two prior data points anchor the design. The Phase 2a study (32 MDD patients, mean baseline MADRS 28.5, mean age 42.8, 47% female) showed a Cohen's d of 1.67 at Week 6 (p=0.0004) and 1.1 at Week 8 (p=0.025) versus placebo[7]. A Cohen's d above 1.0 is considered a very large effect by psychiatry standards, where most approved antidepressants come in at 0.3 to 0.5, though a 32-patient sample has wide confidence intervals and historically Phase 2b trials shrink Phase 2a effect sizes. The PAX-D study (150 patients, pramipexole monotherapy augmentation at 2.5 mg in TRD) produced Cohen's d of 0.87 with high adverse-event burden, supporting the mechanism but illustrating the tolerability problem that ALTO-207's modified-release formulation is specifically designed to solve[8]. Topline guidance is second half 2027[2].

This drug has a 3% estimated chance of eventually reaching approval. The starting point is the historical approval rate for Phase 2 drugs in this area, which is about 24%. The estimate is pulled down mainly by heavier-than-usual blinding, the sponsor's weak approval record, limited earlier-phase results, and a randomized design. The remaining factors are close to average for this stage, so they don't shift the number much in either direction.

Replication risk is the dominant efficacy concern. Phase 2a trials with n=32 routinely report inflated effect sizes that compress in adequately powered Phase 2b studies, even when the underlying mechanism is real. Psychiatric placebo response rates of 35 to 45 percent on MADRS absorb modest drug effects. Tolerability risk is the second-order concern. Pramipexole has well-characterized class-wide adverse events including somnolence, sudden sleep onset, orthostatic hypotension, and impulse-control disorders (pathological gambling, hypersexuality, compulsive shopping) seen in 10 to 20 percent of Parkinson's patients on chronic dopamine agonist therapy. The ondansetron component carries a low risk of QT prolongation that requires routine ECG monitoring in higher-dose contexts. Whether the modified-release formulation cleanly delivers the higher pramipexole exposure without these dopamine-agonist class effects emerging at the 3.2 mg daily dose is an open empirical question. Suicidality monitoring is required under the FDA class-wide warning for all CNS antidepressant trials. Execution risk is moderate; 178 patients across U.S. and U.K. sites is achievable but TRD trials compete for the same patient pool with Spravato post-marketing studies, psilocybin Phase 3 programs (Compass Pathways, Usona Institute), and off-label ketamine clinics that complicate washout. Commercial risk is meaningful even on success. Spravato generated approximately $1 billion in 2024 sales for Johnson & Johnson and has entrenched REMS (Risk Evaluation and Mitigation Strategy) infrastructure[5]; the Spravato REMS program requires patients to receive the drug in a certified healthcare setting and be monitored for two hours afterward, a regulatory constraint that limits convenience but creates a high regulatory and operational bar for new entrants. Auvelity (dextromethorphan/bupropion, Axsome Therapeutics) is approved in MDD with a fast-onset story. A 2028 to 2030 launch of ALTO-207 would need to win on the convenience axis (oral, take-at-home) and on an anhedonia-specific efficacy story to carve out a payer-friendly position.

Watch list with a thesis, not a wait-and-see. ALTO-207 is materially better-positioned than the original framing suggested. The mechanism is publicly disclosed and biologically discussable, a prior positive Phase 2a (Cohen's d 1.1) exists for this exact asset, and an independent peer-reviewed Lancet Psychiatry publication (PAX-D, Cohen's d 0.87) validates the pramipexole-in-TRD hypothesis. ANRO's $264 million cash post-PIPE and guided runway through 2029 substantially reduce the survival-bet framing; the company can credibly fund the ALTO-207 Phase 2b readout, follow-on confirmatory work, and a potential NDA without near-term dilution pressure[4]. That said, the platform-credibility overhang from the ALTO-100 (October 2024) and ALTO-101 misses[3][4] remains real, and the share price reflects investor skepticism. The asymmetric setup for ALTO-207 is: compressed market cap plus known mechanism plus strong but small-sample Phase 2a plus mechanism-aligned independent Phase 2 supportive data. A clean Phase 2b readout in second half 2027 would be substantially de-risking. Pre-readout catalysts to watch are: any disclosure of EEG-biomarker enrichment criteria for the Phase 2b, interim safety/tolerability commentary at investor events, Alto's ALTO-300 (agomelatine-class) data which would either reinforce or further damage the platform thesis, and ANRO 10-Q updates on enrollment pace. The right action for a focused biotech investor is to track this as a discrete asset bet on a validated mechanism rather than as a platform option, and to compare ALTO-207's commercial profile (oral, take-at-home, anhedonia-focused) against Spravato and Auvelity on the dimensions that drive payer formulary decisions.